Article (Scientific journals)
Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: Building model credibility.
Musuamba, Flora T; Skottheim Rusten, Ine; Lesage, Raphaëlle et al.
2021In CPT: Pharmacometrics and Systems Pharmacology, 10 (8), p. 804-825
Peer Reviewed verified by ORBi
 

Files


Full Text
CPT Pharmacom Syst Pharma - 2021 - Musuamba - Scientific and regulatory evaluation of mechanistic in silico drug and.pdf
Author postprint (711.35 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Computer Simulation; Drug Development/legislation & jurisprudence/methods; Humans; Models, Theoretical; Risk Assessment/methods; Terminology as Topic
Abstract :
[en] The value of in silico methods in drug development and evaluation has been demonstrated repeatedly and convincingly. While their benefits are now unanimously recognized, international standards for their evaluation, accepted by all stakeholders involved, are still to be established. In this white paper, we propose a risk-informed evaluation framework for mechanistic model credibility evaluation. To properly frame the proposed verification and validation activities, concepts such as context of use, regulatory impact and risk-based analysis are discussed. To ensure common understanding between all stakeholders, an overview is provided of relevant in silico terminology used throughout this paper. To illustrate the feasibility of the proposed approach, we have applied it to three real case examples in the context of drug development, using a credibility matrix currently being tested as a quick-start tool by regulators. Altogether, this white paper provides a practical approach to model evaluation, applicable in both scientific and regulatory evaluation contexts.
Disciplines :
Engineering, computing & technology: Multidisciplinary, general & others
Author, co-author :
Musuamba, Flora T ;  EMA Modelling and Simulation Working Party, Amsterdam, The Netherlands. ; Federal Agency for Medicines and Health Products, Brussels, Belgium. ; Faculté des Sciences Pharmaceutiques, Université de Lubumbashi, Lubumbashi
Skottheim Rusten, Ine ;  EMA Modelling and Simulation Working Party, Amsterdam, The Netherlands. ; Norvegian Medicines Agency, Oslo, Norway.
Lesage, Raphaëlle;  Biomechanics Section, KU Leuven, Leuven, Belgium. ; Virtual Physiological Human Institute, Leuven, Belgium.
Russo, Giulia;  Department of Drug and Health Sciences, University of Catania, Catania, Italy.
Bursi, Roberta;  InSilicoTrials Technologies, Milano, Italy.
Emili, Luca;  InSilicoTrials Technologies, Milano, Italy.
Wangorsch, Gaby;  EMA Modelling and Simulation Working Party, Amsterdam, The Netherlands. ; Paul-Ehrlich-Institut (Federal Institute for Vaccines and Biomedicines), Langen,
Manolis, Efthymios;  EMA Modelling and Simulation Working Party, Amsterdam, The Netherlands. ; European Medicines Agency, Amsterdam, The Netherlands.
Karlsson, Kristin E ;  EMA Modelling and Simulation Working Party, Amsterdam, The Netherlands. ; Swedish Medical Products Agency, Uppsala, Sweden.
Kulesza, Alexander;  Novadiscovery, Lyon, France.
Courcelles, Eulalie;  Novadiscovery, Lyon, France.
Boissel, Jean-Pierre;  Novadiscovery, Lyon, France.
Rousseau, Cécile F;  Voisin Consulting Life Sciences, Boulogne (Paris), France.
Voisin, Emmanuelle M ;  Voisin Consulting Life Sciences, Boulogne (Paris), France.
Alessandrello, Rossana;  AQuAS - Agency for Health Quality and Assessment of Catalonia, Catalonia, Spain.
Curado, Nuno;  Exploristics, Belfast, UK.
Dall'ara, Enrico;  Insigneo Institute, Sheffield University, Sheffield, UK.
Rodriguez, Blanca ;  Department of Computer Science, British Heart Foundation Centre of Research
Pappalardo, Francesco ;  Department of Drug and Health Sciences, University of Catania, Catania, Italy.
Geris, Liesbet  ;  Université de Liège - ULiège > GIGA > GIGA In silico medecine - Biomechanics Research Unit ; Biomechanics Section, KU Leuven, Leuven, Belgium. ; Virtual Physiological Human Institute, Leuven, Belgium.
More authors (10 more) Less
Language :
English
Title :
Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: Building model credibility.
Publication date :
August 2021
Journal title :
CPT: Pharmacometrics and Systems Pharmacology
ISSN :
2163-8306
Publisher :
Wiley-Blackwell, Us
Volume :
10
Issue :
8
Pages :
804-825
Peer reviewed :
Peer Reviewed verified by ORBi
Funding number :
777123/European Union's Horizon 2020 research/; 772418/ERC CoG/; 214290/Z/18/Z/Basic Biomedical Sciences/; 101017578/European Union's Horizon 2020 research/; 825843/European Union's Horizon 2020 research/; WT_/Wellcome Trust/United Kingdom; 214290/Z/18/Z/Wellcome Trust Fellowship in/; NC/P001076/1/NC3Rs Infrastructure for Impact Award/; 101016496/European Union's Horizon 2020 research/; 101016503/European Union's Horizon 2020 research/
Commentary :
© 2021 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Available on ORBi :
since 29 June 2022

Statistics


Number of views
116 (0 by ULiège)
Number of downloads
96 (0 by ULiège)

Scopus citations®
 
37
Scopus citations®
without self-citations
25
OpenCitations
 
18

Bibliography


Similar publications



Contact ORBi